Literature DB >> 18683165

Tools for the study of ribosome-borne protein folding activity.

Cécile Voisset1, Jean-Yves Thuret, Déborah Tribouillard-Tanvier, Sven J Saupe, Marc Blondel.   

Abstract

In addition to its role in protein synthesis, which involves a peptidyl transferase activity, the ribosome has also been described to be able to assist protein folding, at least in vitro, as presented in a Research Highlight (Das, et al., Biotechnol. J. 2008). This in vitro-described ribosome-borne protein folding activity (RPFA) is yet poorly characterized in vivo, in part because of the lack of tools to study its biological significance. There is substantial evidence documenting RPFA in vitro, and an assay intended to detect this activity in vivo has been set up in bacteria, but this assay is indirect. In this review, we describe the different tools and tests currently available to study RPFA. We put a special emphasis on the various available inhibitors of this activity and in particular, we discuss the use of 6-aminophenanthridine (6AP) and guanabenz (GA), two antiprion drugs that were very recently shown to specifically inhibit RPFA in vitro without any significant effect on the activity of the ribosome in protein synthesis. Therefore, these drugs should allow determining the potential biological role of RPFA. Importantly, the biological activity of 6AP and GA suggest a possible involvement of RPFA in human proteinopathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18683165     DOI: 10.1002/biot.200800134

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  10 in total

Review 1.  Protein folding and aggregation in bacteria.

Authors:  Raimon Sabate; Natalia S de Groot; Salvador Ventura
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

2.  Prion 2016 Oral Abstracts.

Authors: 
Journal:  Prion       Date:  2016       Impact factor: 3.931

3.  A yeast-based assay identifies drugs active against human mitochondrial disorders.

Authors:  Elodie Couplan; Raeka S Aiyar; Roza Kucharczyk; Anna Kabala; Nahia Ezkurdia; Julien Gagneur; Robert P St Onge; Bénédicte Salin; Flavie Soubigou; Marie Le Cann; Lars M Steinmetz; Jean-Paul di Rago; Marc Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

4.  The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition.

Authors:  Yanhong Pang; Sriram Kurella; Cécile Voisset; Dibyendu Samanta; Debapriya Banerjee; Ariane Schabe; Chanchal Das Gupta; Hervé Galons; Marc Blondel; Suparna Sanyal
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

5.  Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation.

Authors:  Aline Bamia; Maha Sinane; Rima Naït-Saïdi; Jamila Dhiab; Frédéric Bihel; Cécile Voisset; Marc Keruzoré; Phu Hai Nguyen; Agathe Bertho; Flavie Soubigou; Sophie Halliez; Marc Blondel; Capucine Trollet; Martine Simonelig; Gaëlle Friocourt; Vincent Béringue
Journal:  Neurotherapeutics       Date:  2021-02-02       Impact factor: 7.620

6.  Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.

Authors:  Nicolas Barbezier; Aymeric Chartier; Yannick Bidet; Anja Buttstedt; Cécile Voisset; Hervé Galons; Marc Blondel; Elisabeth Schwarz; Martine Simonelig
Journal:  EMBO Mol Med       Date:  2011-01       Impact factor: 12.137

7.  Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation.

Authors:  Marc Blondel; Flavie Soubigou; Justine Evrard; Phu Hai Nguyen; Naushaba Hasin; Stéphane Chédin; Reynald Gillet; Marie-Astrid Contesse; Gaëlle Friocourt; Guillaume Stahl; Gary W Jones; Cécile Voisset
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

8.  Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities.

Authors:  Zsuzsanna Sasvari; Stéphane Bach; Marc Blondel; Peter D Nagy
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

9.  The toll-like receptor agonist imiquimod is active against prions.

Authors:  Nassima Oumata; Phu Hai Nguyen; Vincent Beringue; Flavie Soubigou; Yanhong Pang; Nathalie Desban; Catherine Massacrier; Yannis Morel; Carine Paturel; Marie-Astrid Contesse; Serge Bouaziz; Suparna Sanyal; Hervé Galons; Marc Blondel; Cécile Voisset
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  Mechanistic Insight into the Reactivation of BCAII Enzyme from Denatured and Molten Globule States by Eukaryotic Ribosomes and Domain V rRNAs.

Authors:  Biprashekhar Chakraborty; Sayan Bhakta; Jayati Sengupta
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.